Avenue Biosciences

"No life-saving therapy goes unrealised because of production barriers" [1].

Where it wins

• Manufacturability of complex biologics — Uses a library of thousands of signal peptides to boost protein folding, post-translational modifications, and expression, solving the "black box" of the secretory pathway [1].
• AI-driven wet-lab integration — Combines organic biology with machine learning to create high-quality prediction tools, moving beyond the industry's reliance on decades-old, low-throughput signal peptide testing [1].
• Cost and access reduction — Significantly lowers the manufacturing costs of complex, multi-functional proteins (e.g., multispecifics), making therapies for cancer and rare diseases more viable and accessible [1].

Credibility: CEO Tero-Pekka Alastalo and COO Katja Rosti explicitly frame the value around overcoming production bottlenecks for AI-designed and multispecific proteins [1].

• Data-driven engineering — Curates a library of thousands of signal peptides to measure biogenesis efficiency, creating a proprietary dataset for ML models [1].
• High-throughput screening — Uses automated wet-lab processes to test protein variants, generating the data needed to train prediction tools [1].
• Scalable prediction — Sells the resulting AI models and optimized peptide sequences, which scale without marginal cost per additional protein target [1].
• Margin focus — High margins likely sit in the IP (peptide library, algorithms) and services, rather than physical manufacturing [1].

Credibility: The model relies on "wet-lab biology combined with machine learning" to address bottlenecks, a capital-intensive but scalable approach [1].

• Latent Labs — AI-powered programmable biology platform; Avenue differentiates by focusing specifically on signal peptides and manufacturability [1].
• Laigo Bio — Targeted protein-degradation platform; Avenue competes on the upstream expression problem rather than degradation [1].
• TRIMTECH Therapeutics — Protein-degradation therapies; Avenue is a platform provider, not a direct therapy developer [1].
• Traditional CDMOs — Contract manufacturers using standard expression systems; Avenue offers superior AI-driven optimization [1].

Credibility: The funding article positions Avenue alongside these peers, highlighting its unique focus on the secretory pathway [1].

• Manufacturing bottlenecks — Complex proteins (e.g., multispecifics) often fail to produce at scale due to poor folding or secretion [1].
• High production costs — Biologics manufacturing is expensive, limiting access to therapies for rare diseases and cancer [1].
• Limited signal peptide options — Industry relies on a small set of "safe" peptides, ignoring thousands of untapped variants [1].
• Slow discovery timelines — Traditional protein engineering is low-throughput, delaying therapeutic development [1].

Credibility: CEO Alastalo and COO Rosti explicitly cite these as the reasons for the company's existence [1].

The wedge is manufacturability, a critical pain point as biologics become more complex. The main risk is execution on the ML models; if predictions are inaccurate, clients will churn. The opportunity lies in becoming the standard for signal peptide selection, potentially expanding into other expression bottlenecks. The next signal to watch is the first major biopharma partnership announcement, which would validate the platform's commercial viability.

Expand marketing to highlight specific case studies where protein expression was successfully optimized, proving the platform's ROI. Interconnection: This would strengthen the value proposition and address the "black box" perception. Develop a self-serve portal for smaller biotechs to access basic prediction tools, lowering the barrier to entry and building a pipeline for larger clients. Interconnection: This channels the channels and customer relationships blocks. Pursue regulatory endorsements or certifications for the prediction models to build trust with highly regulated pharma partners. Interconnection: This addresses the key resources and cost structure blocks.